Emerging blood biomarkers in Alzheimer’s disease: a proteomic perspective
Authors:
- 27 May 2025
- journal article
- review article
- Published by Elsevier in Clinica Chimica Acta
- Vol. 576, 120397
Abstract
No abstract availableKeywords
This publication has 153 references indexed in Scilit:
- The Limited Role of Alzheimer Disease Blood-Based Biomarkers in Primary CareJAMA Internal Medicine, 2025
- Cerebral Amyloid Angiopathy and Downstream Alzheimer Disease Plasma BiomarkersJAMA Network Open, 2025
- APOE4 , Blood Neurodegenerative Biomarkers, and Cognitive Decline in Community-Dwelling Older AdultsJAMA Network Open, 2025
- Diagnostic Performance of Plasma P‐tau217, NfL, and GFAP for Predicting Alzheimer’s Disease Neuropathology Across Diverse Neurodegenerative SyndromesAlzheimer's & Dementia, 2024
- Plasma Phosphorylated Tau 217 and Aβ42/40 to Predict Early Brain Aβ Accumulation in People Without Cognitive ImpairmentJAMA Neurology, 2024
- Plasma p‐tau217 predicts in vivo brain pathology and cognition in autosomal dominant Alzheimer's diseaseAlzheimer's & Dementia, 2022
- Plasma Aβ42/40 ratio, p‐tau181, GFAP, and NfL across the Alzheimer's disease continuum: A cross‐sectional and longitudinal study in the AIBL cohortAlzheimer's & Dementia, 2022
- Neurologic Prognostication After Cardiac Arrest Using Brain BiomarkersJAMA Neurology, 2022
- Elevated plasma neurofilament light predicts a faster rate of cognitive decline over 5 years in participants with objectively‐defined subtle cognitive decline and MCIAlzheimer's & Dementia, 2021
- A Specific Enzyme-Linked Immunosorbent Assay for Measuring β-Amyloid Protein Oligomers in Human Plasma and Brain Tissue of Patients With Alzheimer DiseaseArchives of Neurology, 2009